DNA methylation analysis of the HIF-1α prolyl hydroxylase domain genes PHD1, PHD2, PHD3 and the factor inhibiting HIF gene FIH in invasive breast carcinomas

Histopathology

Volumn 57, Issue 3, 2010, Pages 451-460

  Huang, Katie T ^a,b   Mikeska, Thomas ^a,b   Dobrovic, Alexander ^a,b   Fox, Stephen B ^a,b  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

breast cancer; DNA methylation; factor inhibiting HIF; hypoxia; prolyl hydroxylase domain

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1ALPHA; PROCOLLAGEN PROLINE 2 OXOGLUTARATE 4 DIOXYGENASE; PROTEASOME;

ARTICLE; BREAST CARCINOMA; CANCER CELL CULTURE; CELL STRAIN HL 60; CONTROLLED STUDY; DNA METHYLATION; GENE EXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; INVASIVE CARCINOMA; LEUKEMIA CELL; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION;

BREAST NEOPLASMS; CARCINOMA; DIOXYGENASES; DNA METHYLATION; FEMALE; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; NUCLEAR PROTEINS; PROCOLLAGEN-PROLINE DIOXYGENASE; REPRESSOR PROTEINS; RNA, MESSENGER; TRANSCRIPTION FACTORS;

EID: 77956628814     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2010.03633.x     Document Type: Article

References (35)

1. Harris AL. Hypoxia - a key regulatory factor in tumour growth. Nat. Rev. Cancer 2002 2 38 47.
2. Semenza GL. Targeting HIF-1 for cancer therapy. Nat. Rev. Cancer 2003 3 721 732.
3. Zhong H, De Marzo AM, Laughner E et al. Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res. 1999 59 5830 5835.
4. Fox SB, Generali DG, Harris AL. Breast tumour angiogenesis. Breast Cancer Res. 2007 9 11.
5. Bos R, Zhong H, Hanrahan CF et al. Levels of hypoxia-inducible factor-1 alpha during breast carcinogenesis. J. Natl Cancer Inst. 2001 93 309 314.
6. Yamamoto Y, Ibusuki M, Okumura Y et al. Hypoxia-inducible factor 1 alpha is closely linked to an aggressive phenotype in breast cancer. Breast Cancer Res. Treat. 2008 110 465 475.
7. Dales JP, Garcia S, Meunier-Carpentier S et al. Overexpression of hypoxia-inducible factor HIF-1alpha predicts early relapse in breast cancer: retrospective study in a series of 745 patients. Int. J. Cancer 2005 116 734 739.
8. Lundgren K, Holm C, Landberg G. Hypoxia and breast cancer: prognostic and therapeutic implications. Cell. Mol. Life Sci. 2007 64 3233 3247.
9. Schindl M, Schoppmann SF, Samonigg H et al. Overexpression of hypoxia-inducible factor 1alpha is associated with an unfavorable prognosis in lymph node-positive breast cancer. Clin. Cancer Res. 2002 8 1831 1837.
10. Trastour C, Benizri E, Ettore F et al. HIF-1 alpha and CA IX staining in invasive breast carcinomas: prognosis and treatment outcome. Int. J. Cancer 2007 120 1451 1458.
11. Patiar S, Harris AL. Role of hypoxia-inducible factor-1 alpha as a cancer therapy target. Endocr. Relat. Cancer 2006 13 S61 S75.
12. Kimbro KS, Simons JW. Hypoxia-inducible factor-1 in human breast and prostate cancer. Endocr. Relat. Cancer 2006 13 739 749.
13. Lando D, Peet DJ, Gorman JJ, Whelan DA, Whitelaw ML, Bruick RK. FIH-1 is an asparaginyl hydroxylase enzyme that regulates the transcriptional activity of hypoxia-inducible factor. Genes Dev. 2002 16 1466 1471.
14. Soilleux EJ, Turley H, Tian YM, Pugh CW, Gatter KC, Harris AL. Use of novel monoclonal antibodies to determine the expression and distribution of the hypoxia regulatory factors PHD-1, PHD-2, PHD-3 and FIH in normal and neoplastic human tissues. Histopathology 2005 47 602 610.
15. Shah R, Smith P, Purdie C et al. The prolyl 3-hydroxylases P3H2 and P3H3 are novel targets for epigenetic silencing in breast cancer. Br. J. Cancer 2009 100 1687 1696.
16. Kristensen LS, Mikeska T, Krypuy M, Dobrovic A. Sensitive Melting Analysis after Real Time-Methylation Specific PCR (SMART-MSP): high-throughput and probe-free quantitative DNA methylation detection. Nucleic Acids Res. 2008 36 e42.
17. Wojdacz TK, Dobrovic A. Methylation-sensitive high resolution melting (MS-HRM): a new approach for sensitive and high-throughput assessment of methylation. Nucleic Acids Res. 2007 35 e41.
18. Wojdacz T, Hansen L, Dobrovic A. A new approach to primer design for the control of PCR bias in methylation studies. BMC Res. Notes 2008 1 54.
19. Nolan T, Hands RE, Bustin SA. Quantification of mRNA using real-time RT-PCR. Nat. Protoc. 2006 1 1559 1582.
20. Cervera AM, Apostolova N, Luna-Crespo F, Sanjuan-Pla A, Garcia-Bou R, McCreath KJ. An alternatively spliced transcript of the PHD3 gene retains prolyl hydroxylase activity. Cancer Lett. 2006 233 131 138.
21. Rasmussen R. Quantification on the LightCycler. In Wittwer C, Hahn M, Kaul K eds. Rapid cycle real-time PCR: methods and application. Heidelberg: Springer Press, 2001 21 34.
22. Vandesompele J, De Preter K, Pattyn F et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol. 2002 3 RESEARCH0034.
23. Candiloro IL, Mikeska T, Hokland P, Dobrovic A. Rapid analysis of heterogeneously methylated DNA using digital methylation-sensitive high resolution melting: application to the CDKN2B (p15) gene. Epigenetics Chromatin 2008 3 7.
24. Fox SB, Braganca J, Turley H et al. CITED4 inhibits hypoxia-activated transcription in cancer cells, and its cytoplasmic location in breast cancer is associated with elevated expression of tumour cell hypoxia-inducible factor 1alpha. Cancer Res. 2004 64 6075 6081.
25. Fong GH, Takeda K. Role and regulation of prolyl hydroxylase domain proteins. Cell Death Differ. 2008 15 635 641.
26. Erez N, Milyavsky M, Eilam R, Shats I, Goldfinger N, Rotter V. Expression of prolyl-hydroxylase-1 (PHD1/EGLN2) suppresses hypoxia inducible factor-1alpha activation and inhibits tumour growth. Cancer Res. 2003 63 8777 8783.
27. Kato H, Inoue T, Asanoma K, Nishimura C, Matsuda T, Wake N. Induction of human endometrial cancer cell senescence through modulation of HIF-1alpha activity by EGLN1. Int. J. Cancer 2006 118 1144 1153.
28. Lee S, Nakamura E, Yang H et al. Neuronal apoptosis linked to EglN3 prolyl hydroxylase and familial pheochromocytoma genes: developmental culling and cancer. Cancer Cell 2005 8 155 167.
29. Percy MJ, Zhao Q, Flores A et al. A family with erythrocytosis establishes a role for prolyl hydroxylase domain protein 2 in oxygen homeostasis. Proc. Natl Acad. Sci. USA 2006 103 654 659.
30. Percy MJ, Furlow PW, Beer PA, Lappin TRJ, McMullin MF, Lee FS. A novel erythrocytosis-associated PHD2 mutation suggests the location of a HIF binding groove. Blood 2007 110 2193 2196.
31. Al-Sheikh M, Moradkhani K, Lopez M, Wajcman H, Préhu C. Disturbance in the HIF-1[alpha] pathway associated with erythrocytosis: further evidences brought by frameshift and nonsense mutations in the prolyl hydroxylase domain protein 2 (PHD2) gene. Blood Cells Mol. Dis. 2008 40 160 165.
32. Kondo Y, Shen L, Cheng AS et al. Gene silencing in cancer by histone H3 lysine 27 trimethylation independent of promoter DNA methylation. Nat. Genet. 2008 40 741 750.
33. Stolze IP, Tian Y-M, Appelhoff RJ et al. Genetic analysis of the role of the asparaginyl hydroxylase factor inhibiting hypoxia-inducible factor (HIF) in regulating HIF transcriptional target genes. J. Biol. Chem. 2004 279 42719 42725.
34. Tan EY, Campo L, Han C et al. Cytoplasmic location of factor-inhibiting hypoxia-inducible factor is associated with an enhanced hypoxic response and a shorter survival in invasive breast cancer. Breast Cancer Res. 2007 9 R89.
35. Morris MR, Maina EN, Morgan NV et al. Molecular genetic analysis of FIH-1, FH, and SDHB candidate tumour suppressor genes in renal cell carcinoma. J. Clin. Pathol. 2004 57 706 711.